Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations

Pharmacogenetics

Volumn 7, Issue 6, 1997, Pages 503-514

  Xie, Hong Guang ^a,b   Xu, Zhen Hua ^a   Ou Yang, Dong Sheng ^a   Shu, Yan ^a   Yang, Dong Liang ^a   Wang, Jun Sheng ^a   Yan, Xiang Dong ^a   Huang, Song Lin ^a   Wang, Wei ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Caffeine; Chinese; Dapsone; Database; Genotyping; Isoniazid; Meta analysis; NAT2; Phenotyping; Sulfadimidine

Indexed keywords

ACYLTRANSFERASE; CAFFEINE; DAPSONE; ISONIAZID; SULFADIMIDINE;

ACETYLATOR PHENOTYPE; ALLELE; ARTICLE; CHINESE; CLINICAL TRIAL; ENZYME DEFICIENCY; GENOTYPE; HUMAN; META ANALYSIS; POINT MUTATION; PRIORITY JOURNAL;

EID: 9844254471     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199712000-00009     Document Type: Article

References (126)

1. Agundez JAG, Olivera M, Ladero JM, Rodriguez-Lescure A, Ledesma MC, Diaz-Rubio M, Meyer UA, Benitez J. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-mediated metabolizers. Pharmacogenetics 1996: 6, 501-512.
2. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990: 39, 533-537.
3. Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, Kadlubar FF, Lucier GW. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993: 14, 1689-1692.
4. Bian JC, Shen FM, Wang JB, Wu Y, Zhang BC. Relationship between genetic polymorphism of N-acetyltransferase and genetic susceptibility to primary hepatocellular carcinoma. Chin J Med Genet 1997: 14, 16-20.
5. Blum M, Grant DM, McBride W, Hein M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal location, and functional expression. DNA Cell Biol 1990: 9, 193-203.
6. Blum M, Demierre A, Grant DM, Hein M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in man. Proc Natl Acad Sci USA 1991: 88, 5237-5241.
7. Bulovskaya LN, Krupkun PG, Bochina TA, Shipkova AA, Pavlova MV, Acetylator phenotypes in patients with breast cancer. Oncology 1978: 35, 185-188.
8. Cartwright RA, Ahmad RA, Barham-Hall D, Glashan RW, Rogers HJ, Higgins E, Kahn MA. Role of N-acetyltransferase phenotypcs in bladder carcinogenesis. A pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982; 2, 842-845.
9. Chen CY, Chen YF, Zou YP, Li HZ, Shang YH. A study on the acetylation phenotypes in the Han and Kazak Chinese populations in Xinjiang area. Northwest Pharm J 1991a: 6, 19-20.
10. Chen CY, Chen YF, Zou YP, Li HZ, Shang YH. Survey of the classification of acetylated metabolism: 113 cases of the Han and Kazak. Clin Pharm J 1991b: 26, 493-494.
11. Chen YF, Chen CY, Zhou J, Li HZ, Wu QM, Shang YH. Studies on acetylation phenotypes among Han, Uygur, Kazak and Xibe nationalities in Xinjiang area. J Shihezi Med Coll 1991: 13, 41-42.
12. Chen YF, Chen CY, Zhou J, Li HZ, Wu QM, Shang YH. Survey of the classification of acetylated metabolism: 63 cases of Weiwuer and Xibo nationalities. Chin Pharm J 1992: 27 244.
13. Clark DWJ. Genetically determined variability in acetylation and oxidation: therapeutic implications. Drugs 1985: 29, 342-375.
14. D'Agostino RB, Weintraub M. Meta-analysis: a method for synthesizing research. Clin Pharmacol Ther 1995: 58, 605-616.
15. Dai DY. Determination of the activity of isoniazid N-acetyltransferase. Chin J Hosp Pharm 1986: 6, 70-71.
16. Dai DY. The colorimetric determination of the isoniazid acetylation metabolism form of 967 cases of 10 races in China. Clin Pharma Bull 1987: 22, 295-297.
17. Dai DY, Miao MH, Guo JF, Liu YX, Li ZX, Luo QS. Studies on the distribution of acetylation phenotypes of 1042 individuals in 14 Chinese nationalities. Chin J Hosp Pharm 1987: 7, 202-204.
18. Deguchi T. Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver. J Biol Chem 1992: 267, 18140-18147.
19. Deguchi T, Mashimo M, Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem 1990: 265, 12757-12760.
20. Deng XH, Zhao XL. Investigation of multiple N-acetyltransferase activity. Chin J Clin Pharmacol 1992: 8, 37-43.
21. Drayer DE, Reidenberg MM. Clinical consequences of polymorphic acetylation of basic drugs. Clin Pharmacol Ther 1977: 22, 251-258.
22. Du BY, Yan BY, Xu MY, Chen DZ. Studies on the method of microbioassay and inactivation type of isoniazid in serum. Chin J Tubercul Respir Dis 1981: 4, 39-42.
23. Ebisawa T, Deguchi T. Structure and restriction fragment length polymorphism of genes from human liver arylamine N-acetyltransferase. Biochem Biophys Res Commun 1991: 177, 1252-1257.
24. Ellard GA. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin Pharmacol Ther 1976: 19, 610-625.
25. Ellard GA, Gammon PT. Acetylator phenotyping of TB patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens. Br J Clin Pharmacol 1977: 4, 5-14.
26. Emery AEH. Methodology in medical genetics. Edinburgh: Churchill Livingstone, 1986: 5.
27. Evans DAP. Pharmacogenetics. Am J Med 1963: 34, 639-662.
28. Evans DAP. Survey of the human acetylator polymorphism in spontaneous disorders. J Med Genet 1984: 21, 243-253.
29. Evans DAP. N-acetyltransferase. Pharmacol Ther 1989: 42, 157-234.
30. Evans DAP. N-acetyltransferases. In: Kalow W, ed. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992: 95-178.
31. Evans DAP, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br Med J 1960: 2, 485-491.
32. Evans DAP, White TA. Human acetylation polymorphism. J Lab Clin Med 1964: 63, 394-403.
33. Ferguson RJ, Doll MA, Rustan TD, Baumstark BR, Hein DW. Syrian hamster monomorphic N-acetyltransferase (NAT1) alleles: amplification, cloning, sequencing, and expression in E. coli. Pharmacogenetics 1994: 4, 82-90.
34. Fishbein E, Segovia DA. Slow acetylator phenotype in systemic lupus erythematosus. Arthritis Rheum 1979: 22, 55-61.
35. Franke S, Klawitz I, Schnakenberg E, Rommel B, van de Ven W, Bullerdiek J, Schloot W. Isolation and mapping of a cosmid clone containing the human NAT2 gene. Biochem Biophys Res Commun 1994: 199, 52-55.
36. Graf T, Broly F, Hoffmann F, Probst M, Meyer UA, Howald H. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Eur J Clin Pharmacol 1992: 43, 399-403.
37. Grant DM. Molecular genetics of the N-acetyltransferases. Pharmacogenetics 1993: 3, 45-50.
38. Grant DM. Molecular genetics of acetyltransferases. In: Bellward GD, ed. Abstracts of the 10th International Symposium on Microsomes and Drug Oxidation, Toronto, 1994: 12-14.
39. Grant DM, Tang BK, Kalow W. Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther 1983: 33, 355-359.
40. Grant DM, Morike K, Eichelbaum M, Meyer UA. Acetylation pharmacogenetics: the slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest 1990: 85, 968-972.
41. Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 1991: 39, 184-191.
42. Grant DM, Blum M, Meyer UA. Polymorphisms of N-acetyltransferase genes. Xenobiotica 1992: 22, 1073-1081.
43. Guan X, Meng YH, Sun JX. Determination of isoniazid levels in urine and its phenotyping of N-acetylation. Bull Chin Antitubercul Assoc 1988: 10, 124.
44. Guan X, Sun JX, Meng YH, Feng WJ. Effect of rifampin on metabolisation of isoniazid. Chin Pharm J 1991, 26, 530-531.
45. Harris CC. Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res 1991: 51 (suppl), 5023-5044.
46. Hashiguchi M, Ebihara A. Acetylation polymorphism of caffeine in a Japanese population. Clin Pharmacol Ther 1992: 52, 274-276.
47. He XQ, Lang MC, Fan LL. Investigation of acetylation phenotyping of isoniazid in 105 individuals of Zhuangzu and Han Chinese from Guangxi area. Chin J Hosp Pharm 1986: 6, 17.
48. Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 1988: 948, 37-66.
49. Hein DW, Rustan TD, Doll MA, Furman EJ, Gray K. Acetyltransferases and susceptibility to chemicals. Toxicol Lett 1992: 64-65, 123-130.
50. Kein DW, Doll MA, Gray K, Rustan TD, Ferguson RJ. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus. Cancer Res 1993: 53, 509-514.
51. Hickman D, Sim E. N-acetyltransferase polymorphism comparison of phenotype and genotype in humans. Biochem Pharmacol 1991: 42, 1007-1014.
52. Hickman D, Risch A, Camilleri JP, Sim E. Genotyping human polymorphic N-acetyltransferase: identification of new slow allotypic variants. Pharmacogenetics 1992: 2, 217-226.
53. Hickman D, Risch A, Buckle V, Spurr NK, Jeremiah ST, McCarthy A, Sim E. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem J 1994: 297, 441-445.
54. Horai Y, Ishizaki T. N-acetylation polymorphism of dapsone in a Japanese population. Br J Clin Pharmacol 1988: 25, 487-494.
55. Horai Y, Zhou HH, Zhang LM, Ishizaki T. N-acetylation phenotyping with dapsone in a mainland Chinese population. Br J Clin Pharmacol 1988: 25, 81-87.
56. Huang CY, Chu JY, Yen TC. Acetylation phenotype in hypertensive patients. KaoHsiung J Med Sci 1992: 8, 1-5.
57. Huang ZL, Nong LS, Mo SZ, Zhu SQ, Lu M, Wu JM, Li XY, Bu WM. Relationship between acetylation phenotypes of sulfadimidine in 170 healthy Zhuangzu Chinese students and their blood types. Bull Youjiang Minority Med Coll 1983: 2, 21-24.
58. Huang ZL, Li XY, Lu M. Relationship between acetylation phenotypes of sulfadimidine in 279 healthy Zhuangzu Chinese students and their blood types. Bull Youjiang Minority Med Coll 1984a: 2, 13-15.
59. Huang ZL, Nong LS, Mo SZ, Zhu SQ, Lu M, Wu JM. Investigation of the acetylation phenotypes of sulfadimidine in 107 healthy Zhuangzu Chinese Students. Information of the Chinese Pharmacological Society 1984b: 1, 1-3.
60. Huang ZY, Lin L, Qiu YQ, Meng H. Use of isoniazid as a substrate for determination of acetylation phenotypes in healthy Chinese subjects. New Drugs Clin Rem 1985: 4, 333-335.
61. Hett KF, David BM, Detchon P, Castleden WM, Kwa R. Acetylation phenotype in colorectal carcinoma. Cancer Res 1987: 47, 1466-1469.
62. Karakaya AE, Cok I, Sardas S, Gogus O, Sardas OS. N-acetyltransferase phenotype of patients with bladder cancer. Hum Toxicol 1986: 5, 333-335.
63. Kuang TJ, Feng L. The rate of isoniazid acetylation in 125 inpatients with pulmonary tuberculosis: use of sulfadimidine as a metabolic probe. Chin J Tubercul Respir Dis 1983: 6, 98-99.
64. Kukongviriyapan V, Lulitanond V, Areejitranusorn C, Kongyingyose B, Laupattarakasem P. N-acetyltransferase polymorphism. Clin Pharmacokinet 1984a: 2, 182-197.
65. Kukongviriyapan V, Lulitanond V, Areejitranusorn C, Kongyingyose B, Laupattarakasem P. N-acetyltransferase polymorphism in Thailand. Hum Hered 1984b: 34, 246-249.
66. Kumana CR, Chan MMY, Wong KL, Wong RWS, Kou MK, Lauder IJ. Lack of association between slow acetylator status and spontaneous lupus erythematosus. Clin Pharmacol Ther 1990: 48, 208-213.
67. Ladero JM, Kwok CK, Jara C, Fernandez L, Silmi AM, Tapia D, Uson AC. Hepatic acetylator phenotype in bladder cancer patients. Ann Clin Res 1985: 17, 96-99.
68. Ladero JM, Gonzalez JF, Benitez J, Vargas E, Fernandez MJ, Baki W, Diaz-Rubio M. Acetylator polymorphism in human colorectal carcinoma. Cancer Res 1991: 51, 2098-2100.
69. Lang NP, Chu DZJ, Hunter CF, Kendall DC, Flammang TJ, Kadlubar FF. Role of aromatic amine acetyltransferase in human colorectal cancer. Arch Surg 1986: 121, 1259-1261.
70. Lee BL, Wong D, Benowitz NL, Sullam PM. Altered patterns of drug metabolism in patients with acquired immunodeficiency. Clin Pharmacol Ther 1993: 53, 529-535.
71. Lee EJD, Lim JME. A study of the acetylator phenotype in normal subjects. Singapore Med J 1981: 22, 117-120.
72. Lee EJD, Lim JME, Feng PH. Acetylator phenotype in Chinese patients with spontaneous systemic lupus erythematosus. Singapore Med J 1985: 26, 295-299.
73. Lee EJD, Zhao B, Moochhala SM, Ngoi SS. Frequency of mutant CYP1A1, NAT2 and GSTM1 alleles in a normal Chinese population. Pharmacogenetics 1994: 4, 355-358.
74. th Southeast Asian and Western Pacific Regional Meeting of Pharmacologists (SEA/WP RMP), Beijing, 1988: 314.
75. Liang SQ, Cui ZJ. Relationship between acetylation phenotype of isoniazid and short-term chemotherapy. People's Military Medicine 1989: 2, 71-72.
76. Lin HJ, Han CY, Lin BK, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, Blacks. Hispanics, and Whites: application to metabolic epidemiology. Am J Hum Genet 1993: 52, 827-834.
77. Lin HJ, Han CY Lin BK, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994: 4, 125-134.
78. Lin M, Xu YH, Ren JX, Tao BG, Xue SZ. Study on the N-acetyltransferase phenotypic Polymorphism and allelic frequency in the healthy students from the high schools in Nanjing area. Hered Dis 1991: 8, 113-114.
79. Lin M, Wen YJ, Xu YH, Tao BG, Jin JX, Zhou ZP, Mao LM, Chen AT, Xue SZ. Study on the N-acetyltransferase polymorphism among primary liver cancer patients. Carcinogen Teratogen Mutagen 1994: 6, 1-3.
80. Lower GM, Nilsson T, Nelson CE, Wolf H, Gamski TE, Bryan GT. N-acetyltransferase genotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Envir Health Perspect 1979: 29, 71-19.
81. Lunde PKM, Frislid K, Hanstern V. Disease and acetylation polymorphism. Clin Pharmacokinet 1977: 2, 182-197.
82. Martinez C, Agundez JAG, Olivera M, Martin R, Ladero JM, Benitez J. Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics 1995: 5, 207-214.
83. Mashimo M, Suzuki T, Abe M, Deguchi T. Molecular genotyping of N-acetylation polymorphism to predict phenotype. Hum Genet 1992; 90, 139-143.
84. Meng RY, Acetylation phenotypes and esophagus cancer. Chengdu Air Force J Pharm Sci 1990: 2, 12.
85. Meng RY, Zeng JZ. Preliminary investigation of the relationship between acetylation metabolizer phenotype and esophagus cancer. West China J Pharm Sci 1991: 6, 25-26.
86. Miller ME, Cosgriff JM. Acetylator phenotype in human bladder cancer. J Urol 1983: 130, 65-66.
87. Mommsen S, Barford NM, Angaard J. N-acetyltransferase phenotype in the urinary bladder carcinogenesis of a low risk population. Carcinogen 1985: 6, 199-201.
88. Nebert DW. Role of genetics and drug metabolism in human cancer risk. Mutat Res 1991: 247, 267-281.
89. Ohsako S, Deguchi T. Cloning and expression of cDNA for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J Biol Chem 1990: 265, 46 30-46 34.
90. Ong ML, Mant TG, Veerapen K, Fitzgerald D, Wang F, Manivasagar M, Bosco JJ. The lack of relationship between acetylator phenotype and idiopathic systemic lupus erythematosus in a Southeast Asia population: a study of Indians, Malays and Malaysian Chinese. Br J Rheumatol 1990: 29, 462-464.
91. Peng RJ, Rong ZX, Lin ZY, Lin HZ, Yang LH, Peng B, Zhao XL. A study on correlation between the acetylalion phenotypes of sulfadimidine and G6PD activity in 117 healthy Chinese students. Chin Pharmacol Bull 1989: 5, 248.
92. Perry HM, Late toxicity to hydralaxine resembling systemic lupus erythematosus or rheumatoid arthritis. Am J Med 1972: 54, 58-72.
93. Philip PA, Rogers HJ, Millis RR, Rubens RD, Cartwright RA. Acetylator status and its relationship to breast cancer and other diseases of the breast. Eur J Cancer Clin Oncol 1987: 23, 1701-1706.
94. Probst MR, Blum M, Fasshauer I, D'Orazio D, Meyer UA, Wild D. The role of the human acetylation polymorphism in the metabolic activation of the food carcinogen 2-amino-3-methylimidazo[4, 5-f]quinoline (IQ). Carcinogenesis 1992: 13, 1713-1717.
95. Ratain MJ, Mick R, Janisch L, Berezin F, Schilsky RL, Vogelzang NJ, Kut M. Individualized dosing of amonatide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics 1996: 6, 93-101.
96. Relling MV. Polymorphic drug metabolism. Clin Pharm 1989: 8, 852-863.
97. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991: 49, 13-17.
98. Roots I, Drakoulis N, Brockmoller J. Polymorphic enzymes and cancer risk: concepts, methodology and data review. In: Kalow W. ed. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992: 815-841.
99. Rothman N, Hayes RB, Bi WF, Caporaso N, Broly F, Woosley RL, Yin SN, Feng PW, You XJ, Meyer UA. Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics 1993: 3, 250-255.
100. Sardas S, Karakaya AE, Sardas OS. Acetylation phenotype in patients with systemic lupus erythematosus. Arthritis Rheum 1986: 29, 1412.
101. Sardas S, Cok I, Sardas OS, Ilhan O, Karakaya AE. Polymorphic N-acetylation capacity in breast cancer patients. Int J Cancer 1990: 46, 1138-1139.
102. Sunahara S, Urano M, Ogawa M, Genetical and geographic studies on isoniazid inactivation. Science 1961: 134, 1530-1531.
103. Sunahara S, Urano M, Lin HT, Cheg TJ, Jarumilinda A. Further observation on triamodality of frequency distribution curve of biologically active isoniazid blood levels and 'cline' in frequencies of alleles controlling isoniazid inactivation. Acta Tubercul Pneumol Scand 1963: 43, 181-195.
104. Vatsis KP, Martell KJ, Weber WW. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci USA 1991: 88, 633-6337.
105. Vatsis KP, Weber WW, Bell DA, Dupret J-M, Evans DAP, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995: 5, 1-17.
106. Vogel F, Motulsky AG. Human genetics: problems and approaches. 2nd ed. Berlin: Springer-Verlag, 1986: 129-130.
107. Wang KY, Liao XM, Jing ZM, Ma CY, Gao B. Determination of the acetylator phenotypes of sulfadimidine in 200 healthy Zangzu (Tibetan) Chinese volunteers [Abstract]. Inform Chin Pharmacol Soc 1991: 8, 24.
108. Weber WW, Hein DW. Clinical Pharmacokinetics of isoniazid. Clin Pharmacokinet 1979: 4, 401-422.
109. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985: 37, 25-79.
110. Wohlleb JC, Hunter CF, Blass B, Kadlubar FF, Chu DZJ, Lang NP. Aromatic amine acetyltransferase as a marker for colorectal cancer: environmental and demographic associations. Int J Cancer 1990: 46, 22-30.
111. Wolkenstein P, Cariere V, Charue D, Bustuji-Garin S, Revuz J, Roujeau J-C, Beaune P, Bugot M. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995: 5, 255-258.
112. Wood AJJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991: 20, 350-373.
113. Xie HG, Zhou HH. Genetic polymorphism of drug acetylation. Hunan Med J 1993: 10, 159-160.
114. Xie HG, Zhou HH. Genetically epidemiological characterization of drug acetylation in major Chinese nationalities. Chin J Pharmacoepidemiol 1995: 4, 87-89.
115. Xie HG, Xu ZH, Luo X, Huang SL, Zeng FD, Zhou HH. Genetic polymorphisms of debrisoquine and S-mephenytoin oxidation metabolism in Chinese populations: a meta-analysis. Pharmacogenetics 1996: 6, 235-238.
116. Xie HG, Zhou HH. Medical Progress in China '96: pharmacogenetics. Natl Med J China 1997: 77, 77-78.
117. Xu XM, Jiang WD. Debrisoquine hydroxylation and sulfamethazine acetylation in a Chinese population. Acta Pharmacol Sin 1990: 11, 385-388.
118. Yan DX. Determination of isoniaxid and acetylisoniazid in urine for phenotyping isoniaxid inactivators. Chin J Tubercul Respir Dis 1983: 6, 71-73.
119. Yang GX, Wang L, Wang SX, Pan YL. Comparison of isoniazid acetylation phenotypes in the Mongol minority population with that in the Han Chinese. Inner Mongol J Pharm Sci 1986: 5, 10-13.
120. Yang GX, Wang L, Wang SX, Pan YL. Comparison of acetylation phenotypes of isoniazid between the Mongol and Han nationalities. Chin J Hosp Pharm 1989: 9, 352-354.
121. Yu MC, Skipper PL, Taghizadeh K, Tannenbaum SR, Chan KK, Henderson BE, Ross RK. Acetylator phenotype, aminobiphenylhemoglobin adult levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. J Natl Cancer Inst 1994: 86, 712-715.
122. Yu XY, Zhao XL. High-performance liquid chromatography in comparison with colorimetry for determination of acetylator phenotypes. Chin J Clin Pharmacol 1990: 6, 87-91.
123. Yu XY, Zhao XL, Zeng CG, Yang MT, Zhou HN, Zhang YQ. Acetylator phenotypes and its relationship to breast tumor. Chin J Cancer 1990: 9, 205-208.
124. Zeng JZ, Jiang XH. The colorimetric determination of isoniazid and acetylisoniazid in urine and comparison of acetylation phenotypes between the Han and Zangzu (Tibetan) Chinese of 155 healthy volunteers. Chin J Hosp Pharm 1984: 4, 483-486.
125. Zhang FL, Chen X. Determination of acetylation phenotype by sulfadimidine in student volunteers in Hunan. Chin J Clin Pharmacol 1988: 4, 67-70.
126. Zhao XL, Wang JH, Peng B, Huang M, Xing LY, Zeng GX. The investigation on acetylator phenotype of the Li nationality in Hainan Island. Abstracts of the 5th Southeast Asian and Western Pacific Regional Meeting of Pharmacologists (SEA/WP RMP). Beijing, 1988: 316.